$ATEX

Fleischhauer Mark sold $279K of ATEX

Fleischhauer Mark sold 3,500 shares of Anterix Inc. (ATEX) at $79.83 ($0.28M total) on 2026-06-15.

Original reporting
SEC EDGAR · Fleischhauer Mark
Published Jun 17, 2026, 11:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATEX
Neutral
high confidence
Mentioned
$ATEX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATEXNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 3,500 shares at ~$79.8294 on 2026-06-15, with holdings after the sale of 12,769 shares.

02

Market read

This is a routine insider-sale filing; it may slightly influence sentiment but lacks fundamental company catalysts in the text.

03

What to watch

Traders may want to check whether other insiders sold/bought around the same period and whether the director’s remaining holdings changed materially versus prior filings.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-17; transaction dated 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Anterix Inc. (ATEX).

Company-level read

Ticker impact

$ATEXNeutralHigh confidence
Context

Anterix director Mark Fleischhauer sold 3,500 ATEX shares in an open-market transaction on 2026-06-15 for ~$279.4K.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with broader insider activity or material company news.

Evidence & confidence

The filing is a standard SEC Form 4 insider transaction with no 10b5-1 plan and no accompanying fundamental catalyst in the text.

Market effects

Minimal; single insider sale does not change sector fundamentals based on the provided text.

None indicated.

None indicated.

Counterpoint

No 10b5-1 plan is noted, but the sale could be for diversification/tax rather than a bearish view; one transaction is not a trend.

Key entities

  • Anterix Inc.

    Subject of the Form 4 insider transaction; director Mark Fleischhauer sold shares.

  • Mark Fleischhauer

    Director who executed the open-market sale; no pre-arranged 10b5-1 plan indicated.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATEXMed

Is Anterix (ATEX) Quietly Reframing Its Connectivity Moat With New 900 MHz FCC Flexibility?

Anterix (ATEX) gained attention after the FCC approved expanded 900 MHz broadband use and granted it a license for satellite testing. This could broaden its network applications and reinforce its investment narrative, though profitability currently relies heavily on noncash spectrum gains. Analysts project $6.9M revenue and $935K earnings by 2028, with a potential 36% downside from current prices.

$ATEXMed

Anterix (ATEX) Q1 2027 Earnings Call Transcript

Anterix (ATEX) reported Q1 2027 revenue of $2M, up from $1.4M YoY, with net income of $240K. Operating expenses decreased to $12.9M. The company has $116M in cash, no debt, and $226.7M left for share repurchases. Management highlighted 12 active deals, spectrum clearing progress, and support for SpaceX's FCC proposal. CFO warned of potential higher costs if spectrum clearing is accelerated.

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Anterix Inc. Reports First Quarter Fiscal Year 2027 Results Woodland Park, NJ – August 11, 2026 – Anterix (NASDAQ: ATEX) today announced its first quarter fiscal 2027 results and filed its Form 10-Q for the three months ended June 30, 2026. Financial and Operational Highlights –

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2